Loading
A phase 2/3 trial of Ivonescimab, Enfortumab vedotin and Pembrolizumab in bladder & urothelial cancer, run by Summit Therapeutics, now recruiting.
A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma is a phase 2/3 interventional study registered as NCT07815665 by Summit Therapeutics, with 800 participants planned, started 2026-09-10 and due to reach its primary completion in 2030-10-31. Interventions recorded: Ivonescimab Dose 1, enfortumab vedotin (EV), Pembrolizumab, Ivonescimab Dose 2 and Ivonescimab RP3D.
Shares Enfortumab vedotin, Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Enfortumab vedotin, Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Enfortumab vedotin, Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Enfortumab vedotin, Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Enfortumab vedotin, Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Antibody-drug conjugate (ADC), Pembrolizumab and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Enfortumab vedotin, Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Antibody-drug conjugate (ADC) and the tag pipeline.